Monthly Archives: September 2013

The First Day of Obamacare: Is US Pharma Ready?

by Tom Norton For more than three years, the US pharmaceutical industry has known that today would arrive. So this is it. The first day that eligible U.S. citizens can sign up for Obamacare — and enjoy the prospect of prescription drug insurance, effective January 1st, 2014. I have spent the last week surveying many […]
Posted in Guest Blog, healthcare, Legal, Market Access, pricing, R&D, Regulatory, Sales, Strategy | Tagged , , , , , , , , | 1 Comment

The Little Orphan That Could: How Alexion is Going Global

Since the initial FDA approval of its flagship orphan drug Soliris in 2007, Alexion Pharmaceuticals has done well for itself as a small biotech firm that focuses on ultra-rare disease. So well in fact, that instead of partnering, the company has taken global expansion into its own hands. Apart from a pipeline that includes asfotase […]
Posted in Biotech, Global, Manufacturing, Market Access, Orphan Drugs, Strategy, Supply Chain | Tagged , , , , , , , , | Leave a comment

Storytelling Partnerships – the New Face of Big Pharma Marketing

Doing deals with storytellers could be as important for pharma as collaborating with research scientists, writes Peter Houston. Leading advertising trade publication Ad Week ran an interesting feature on the ‘New Face of Big Pharma Marketing’ this week. The piece outlines the changes that Obamacare combined with public distrust of pharma is forcing on marketers, noting […]
Posted in E-Media, Europe, Guest Blog, Marketing, Op-Ed, Strategy | Tagged , , , , , , | Leave a comment

Congress Clarifies Drug Compounding, Tracking Policies

Public outrage over deaths from contaminated injectables produced by large compounding pharmacies, along with rising concerns about counterfeit and unauthorized drugs entering the U.S. market, managed to lift the stalemate on Capitol Hill long enough to generate agreement on reform legislation. After months of public hearings and negotiations, Democrat and Republican leaders of the House […]
Posted in FDA, Legal, Manufacturing, Regulatory, Safety, Strategy, Supply Chain, Technology | Tagged , , , , , , , , , , , , , | Leave a comment

PhRMA Research and Hope Awards Gives Industry a Shot in the Arm

Vaccines–once the neglected also ran in big Pharma’s armamentarium of innovations–received top billing at PhRMA’s annual Research and Hope awards held at the Washington Newseum on September 11.  More than 200 industry executives, politicians and scientists recognized the accomplishments of three separate teams in developing and building access to  preventive vaccines.
Posted in Events, healthcare, R&D | Tagged , , , , , , , , , , , , | Leave a comment
  • Categories

  • Meta